{
    "clinical_study": {
        "@rank": "3302", 
        "arm_group": [
            {
                "arm_group_label": "Deferitazole (disodium salt, granule)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Deferitazole (disodium salt, tablet)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Deferitazole (magnesium hydroxide salt)", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the pharmacokinetic profiles of deferitazole after\n      administration of granule and tablet formulations of a deferitazole disodium salt to a\n      capsule formulation of deferitazole magnesium hydroxide salt (reference formulation) in\n      healthy adult subjects."
        }, 
        "brief_title": "Pharmacokinetics of Granule and Tablet Formulations of Deferitazole (Disodium Salt) and a Capsule Formulation of Deferitazole (Magnesium Hydroxide Salt)", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age 18-65 years inclusive at the time of consent.\n\n          2. Must be considered \"healthy\".\n\n          3. Serum ferritin, hemoglobin and erythrocyte indices (packed cell volume, mean\n             corpuscular volume and mean corpuscular hemoglobin concentration) within normal\n             range.\n\n          4. Willingness to comply with any applicable contraceptive requirements of the protocol\n             and is:\n\n               -  Male, or\n\n               -  Female of non-childbearing potential (defined as a female who is post-menopausal\n                  )\n\n               -  Non-pregnant, non-lactating female\n\n               -  Females must be at least 90 days post partum or nulliparous.\n\n          5. Body weight equal to or greater than 60kg.\n\n          6. Ability to swallow a dose of the investigational product.\n\n        Exclusion Criteria:\n\n          1. Subject has a clinically significant history or a disorder detected during the\n             medical interview/physical examination.\n\n          2. Acute illness.\n\n          3. Oral condition:\n\n               -  Has history of oral surgery (including extractions) within 4 weeks, operative\n                  dental work within 7 days, or a presence of any clinically significant oral\n                  pathology (as determined by the investigator) including lesions, sores or\n                  inflammation which would interfere with assessments.\n\n               -  Has fixed retainers, orthodontic appliances, or either maxillary and/or\n                  mandibular dentures or other appliances which may interfere with swilling or\n                  tasting the formulations.\n\n               -  Has current or recurrent disease that could affect the mouth and interfere with\n                  the taste assessment.\n\n               -  Has severe gingivitis, periodontitis or rampant caries.\n\n               -  Has the presence of oral or peri-oral ulceration including herpetic lesions\n\n               -  Has elective dentistry scheduled during the study duration.\n\n          4. Subject has a history of thyroid disorder that has not been stabilized on thyroid\n             medication or treatment.\n\n          5. History of alcohol or other substance abuse within the year.\n\n          6. A positive screen for alcohol or drugs of abuse.\n\n          7. Confirmed systolic blood pressure >139mmHg or <89mmHg, and diastolic blood pressure\n             >89mmHg or<49mmHg.\n\n          8. Routine consumption of more than 2 units of caffeine per day or subjects who\n             experience caffeine withdrawal headaches.\n\n          9. Male subjects who consume more than 3 units of alcohol per day. Female subjects who\n             consume more than 2 units of alcohol per day.\n\n         10. A positive human immunodeficiency virus antibody screen, hepatitis B surface antigen,\n             or hepatitis C virus antibody.\n\n         11. Current use of any other medication (including over-the-counter, herbal, or\n             homeopathic preparations)\n\n         12. Current use of iron supplements and/or multivitamins.\n\n         13. Use of tobacco in any form (e.g., smoking or chewing) or other nicotine-containing\n             products.\n\n         14. Donation of blood or blood products (e.g., plasma or platelets) within 60 days."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02065401", 
            "org_study_id": "SPD602-112"
        }, 
        "intervention": [
            {
                "arm_group_label": "Deferitazole (disodium salt, granule)", 
                "description": "Single oral dose of 1500 mg administered on Day 1", 
                "intervention_name": "Deferitazole (disodium salt, granule)", 
                "intervention_type": "Drug", 
                "other_name": "SPD602, SSP-004184, SSP-004184SS"
            }, 
            {
                "arm_group_label": "Deferitazole (disodium salt, tablet)", 
                "description": "Single oral dose of 1500 mg administered on Day 1", 
                "intervention_name": "Deferitazole (disodium salt, tablet)", 
                "intervention_type": "Drug", 
                "other_name": "SPD602, SSP-004184, SSP-004184SS"
            }, 
            {
                "arm_group_label": "Deferitazole (magnesium hydroxide salt)", 
                "description": "Single oral dose of 2400 mg administered on Day 1", 
                "intervention_name": "Deferitazole (magnesium hydroxide salt)", 
                "intervention_type": "Drug", 
                "other_name": "SPD602, SSP-004184AQ, SSP-004184"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Magnesium Hydroxide"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 18, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Miami", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "33014"
                }, 
                "name": "Clinical Pharmacology of Miami"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 1, Open-label, Randomized, 3-Period, Relative Bioavailability Study Comparing the Pharmacokinetics of Granule and Tablet Formulations of Deferitazole (Disodium Salt) and a Capsule Formulation of Deferitazole (Magnesium Hydroxide Salt), Each Administered as a Single Oral Dose", 
        "overall_status": "Suspended", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "AUC of disodium salt granule, disodium salt tablet, and magnesium hydroxide salt", 
                "measure": "Area Under the Plasma Concentration-time Curve (AUC) of Deferitazole", 
                "safety_issue": "No", 
                "time_frame": "Up to 120 hours post-dose"
            }, 
            {
                "description": "Cmax of disodium salt granule, disodium salt tablet, and magnesium hydroxide salt", 
                "measure": "Maximum Plasma Concentration (Cmax) of Deferitazole", 
                "safety_issue": "No", 
                "time_frame": "Up to 120 hours post-dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02065401"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Taste of Deferitazole", 
                "safety_issue": "No", 
                "time_frame": "Immediately after dose and 5 minutes post-dose"
            }, 
            {
                "description": "Compare the pharmacokinetic profile of granule formulation with pharmacokinetic profile of tablet formulation", 
                "measure": "Bioequivalence of Deferitazole Disodium Salt Granule Formulation With Tablet Formulation", 
                "safety_issue": "No", 
                "time_frame": "Up to 120 hours post-dose"
            }
        ], 
        "source": "Shire", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shire", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "March 2014", 
        "why_stopped": "Study activities have been suspended while sponsor evaluates nonclinical (rat) findings.The\n    potential relevance of these findings to humans, if any, is unknown."
    }
}